Trelegy (fluticasone furoate umeclidinium bromide vilanterol trifenatate): Reviews and patient testimonials
Medication indications
Trelegy
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist (for effects on symptom control see section 5.1).
Molecule: fluticasone furoate, umeclidinium bromide, vilanterol trifenatate
Patients' opinions on Trelegy
In brief
General satisfaction level: 6.50/10 Learn more
Treatment's effectiveness: 6.67/10 Learn more
Ease of use: 6.83/10 Learn more
Adherence to prescription: 9.33/10 Learn more
Detected side effects: 5.20/10 Learn more
Improvement in the quality of life: 6.33/10 Learn more
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community